Revance Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Revance Therapeutics

09/05/2024 22:01

* Revance Therapeutics Inc  RVNC.OQ  reported a quarterly
adjusted
loss of 58 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -74 cents.  The mean expectation of ten analysts
for the quarter was for a loss of 75 cents per share. Wall
Street expected results to range from $-1.19 to -50 cents per
share.
    * Revenue rose 110.6% to $103.87 million from a year ago;
analysts
expected $56.63 million. 
    * Revance Therapeutics Inc's reported EPS for the quarter
was a
loss of 58 cents​.
    * The company reported a quarterly loss of $53.15 million.
    * Revance Therapeutics Inc shares had fallen by 13.2% this
quarter and lost 51.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 23.7%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Revance
Therapeutics Inc is $12.00 

This summary was machine generated from LSEG data May 9 at 09:00
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.75          -0.58          Beat
 Dec. 31 2023      -0.72          -0.62          Beat
 Sep. 30 2023      -0.85          -1.63          Missed
 Jun. 30 2023      -0.78          -0.80          Missed